Jan Hendrik Egberts
Chief Executive Officer at Veritas Investments
Net worth: 73 916 $ as of 2024-03-30
Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Kees Groen | M | 63 |
ORCA Therapeutics BV
ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
Adam F. Cohen | M | 72 |
Centre for Human Drug Research
Centre for Human Drug Research BiotechnologyHealth Technology The Centre for Human Drug Research provides clinical drug research services. The private company is based in Leiden, Netherlands. Adam F. Cohen has been the CEO of the Dutch company since 1987. | 37 years |
Mireille Sanders | F | 56 | 5 years | |
Daniel Schneider | M | - | 6 years | |
Elina van Herwijnen | F | - |
ViroClinics Biosciences BV
ViroClinics Biosciences BV Pharmaceuticals: MajorHealth Technology ViroClinics Biosciences BV engages in the provision of diagnostic and clinical trial solutions. It offers research and development, preclinical, clinical trial operation, diagnostic testing, virus discovery, and quality assurance services. The company was founded by Albert Osterhaus in 2001 and is headquartered in Rotterdam, the Netherlands. | 17 years |
Deborah Jorn | F | 66 | 5 years | |
Neal Shore | M | - | 2 years | |
Johanna Holldack | M | - | 7 years | |
Thomas Michael Tarnowski | M | 48 |
ViroClinics Biosciences BV
ViroClinics Biosciences BV Pharmaceuticals: MajorHealth Technology ViroClinics Biosciences BV engages in the provision of diagnostic and clinical trial solutions. It offers research and development, preclinical, clinical trial operation, diagnostic testing, virus discovery, and quality assurance services. The company was founded by Albert Osterhaus in 2001 and is headquartered in Rotterdam, the Netherlands. | - |
Olaf de Jager | M | - |
ViroClinics Biosciences BV
ViroClinics Biosciences BV Pharmaceuticals: MajorHealth Technology ViroClinics Biosciences BV engages in the provision of diagnostic and clinical trial solutions. It offers research and development, preclinical, clinical trial operation, diagnostic testing, virus discovery, and quality assurance services. The company was founded by Albert Osterhaus in 2001 and is headquartered in Rotterdam, the Netherlands. | 18 years |
Ramon Alemany | M | - |
ORCA Therapeutics BV
ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
Maja Bergmann | F | - | 5 years | |
Anders Neijber | M | - | 3 years | |
Patricia Kelly | F | - | 4 years | |
Susanne Strauss | M | - | 4 years | |
Jan Benschop | M | - |
Mellon Medical BV
Mellon Medical BV Medical SpecialtiesHealth Technology Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands. | - |
Mark R. Straley | M | 63 |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | 9 years |
Jabine T. M. van der Meijs | M | 58 |
Centre for Human Drug Research
Centre for Human Drug Research BiotechnologyHealth Technology The Centre for Human Drug Research provides clinical drug research services. The private company is based in Leiden, Netherlands. Adam F. Cohen has been the CEO of the Dutch company since 1987. | - |
Oskar Slotboom | M | - |
Mellon Medical BV
Mellon Medical BV Medical SpecialtiesHealth Technology Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands. | - |
Mark R.L. Krul | M | - |
ORCA Therapeutics BV
ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
Rob de Ree | M | - |
Mellon Medical BV
Mellon Medical BV Medical SpecialtiesHealth Technology Mellon Medical BV manufactures and develops surgical suturing devices. The firm’s suturing device, the Switch, is designed for surgeons who perform the challenging operations and can easily be rotated in the hand because of its pencil-like shape. The company was founded in April 2013 by Mark Vrancken Peeters and is headquartered in Nijmegen, the Netherlands. | - |
George Church | M | 69 |
Harvard Medical School
| 38 years |
Frans van den Berg | M | - |
Lead Pharma Holding BV
Lead Pharma Holding BV Pharmaceuticals: MajorHealth Technology Lead Pharma Holding BV develops small-molecule drugs for the treatment of autoimmune diseases and cancer. It specializes in medicinal, computational, and protein chemistry, x-ray crystallography, cell biology, and integration x-omics. The company was founded by Ad van Gorp, Leon de Windt, and Pieter Doevendans in 2007 and is headquartered in Oss , the Netherlands. | - |
Hans Bunschoten | M | - |
ViroClinics Biosciences BV
ViroClinics Biosciences BV Pharmaceuticals: MajorHealth Technology ViroClinics Biosciences BV engages in the provision of diagnostic and clinical trial solutions. It offers research and development, preclinical, clinical trial operation, diagnostic testing, virus discovery, and quality assurance services. The company was founded by Albert Osterhaus in 2001 and is headquartered in Rotterdam, the Netherlands. | 16 years |
Barbara McNeil | M | 83 |
Harvard Medical School
| 41 years |
Jerry de Groot | M | - |
Sigmascreening BV
Sigmascreening BV Wholesale DistributorsDistribution Services Sigmascreening BV develops new diagnostic products for breast cancer screening. It offers its products to improve the digital mammography in the screening. The company was founded by Kees Grimbergen, Ard den Heeten and Emile Konps in July 2010 and is headquartered in Amsterdam, the Netherlands. | - |
Ivo Aarninkhof | M | - |
Sigmascreening BV
Sigmascreening BV Wholesale DistributorsDistribution Services Sigmascreening BV develops new diagnostic products for breast cancer screening. It offers its products to improve the digital mammography in the screening. The company was founded by Kees Grimbergen, Ard den Heeten and Emile Konps in July 2010 and is headquartered in Amsterdam, the Netherlands. | - |
Kees Grimbergen | M | - |
Sigmascreening BV
Sigmascreening BV Wholesale DistributorsDistribution Services Sigmascreening BV develops new diagnostic products for breast cancer screening. It offers its products to improve the digital mammography in the screening. The company was founded by Kees Grimbergen, Ard den Heeten and Emile Konps in July 2010 and is headquartered in Amsterdam, the Netherlands. | - |
Geoffrey Coy | M | - | 5 years | |
Erik van den Berg | M | 51 |
Lead Pharma Holding BV
Lead Pharma Holding BV Pharmaceuticals: MajorHealth Technology Lead Pharma Holding BV develops small-molecule drugs for the treatment of autoimmune diseases and cancer. It specializes in medicinal, computational, and protein chemistry, x-ray crystallography, cell biology, and integration x-omics. The company was founded by Ad van Gorp, Leon de Windt, and Pieter Doevendans in 2007 and is headquartered in Oss , the Netherlands. | 8 years |
Victor W. van Beusechem | M | - |
ORCA Therapeutics BV
ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
Gerardus Wilhelmus van Odijk | M | 67 |
Centre for Human Drug Research
Centre for Human Drug Research BiotechnologyHealth Technology The Centre for Human Drug Research provides clinical drug research services. The private company is based in Leiden, Netherlands. Adam F. Cohen has been the CEO of the Dutch company since 1987. | 5 years |
Wenliang Dong | M | - |
ORCA Therapeutics BV
ORCA Therapeutics BV Pharmaceuticals: GenericHealth Technology ORCA Therapeutics BV designs and develops virotherapy drugs. The firm is a biopharmaceutical company focusing on the development of new anti-cancer treatments using Oncolytic Replication Competent Agents. It has a platform of technologies which are predominantly based on engineered oncolytic adenoviruses. The company was founded in 2005 and is headquartered in Nijmegen, the Netherlands. | - |
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Tone Kvåle | F | 55 | 8 years | |
Jaap Blaak | M | 83 | 11 years | |
Ludvik Sandnes | M | - | 6 years | |
Paul Sekhri | M | 66 | 8 years | |
Kjetil Hestdal | M | 64 | 21 years | |
Synne Hermansen Røine | F | 45 | 6 years | |
Tom Edward Pike | M | 64 | 6 years | |
Per Anders Göte Samuelsson | M | 63 | 8 years | |
Marco Renoldi | M | 67 | 8 years | |
Hilde Hermansen Steineger | M | 58 | 7 years | |
Gry Stensrud | M | 54 | 15 years | |
Anne Hovi Worsøe | F | 60 | - | |
Rainer Boehm | M | 63 | 4 years | |
Anders Tuv | M | 46 | - | |
Mark J. Baric | M | 65 | 5 years | |
Fredrik Haavind | M | - | - | |
Joanna Horobin | M | 69 | 7 years | |
Gwen Melincoff | M | 72 | 3 years | |
Gisela Schwab | M | 67 | 5 years | |
Lars Nieba | M | 56 | - | |
Jean Whitehead Frydman | F | 71 | - | |
David L. MacDonald | M | - |
Agendia, Inc.
Agendia, Inc. Pharmaceuticals: MajorHealth Technology Agendia, Inc. operates as a molecular diagnostics company. It develops and markets FFPE-based genomic diagnostic products, which help support physicians with their treatment decisions. Agendia?s tests can help physicians assess a patient?s individual risk for metastasis, it benefits from chemo, hormonal or combination therapy. The company was founded by Laura van't Veer and Ren? Bernards in 2003 and is headquartered in Irvine, CA. | 3 years |
Deni M. Zodda | M | 70 | 2 years | |
Charles Edward Swain | M | - |
Stanford Graduate School of Business
| 2 years |
Eric Stern | M | 60 |
Stanford Graduate School of Business
| 2 years |
Gregg Bennett | M | - |
Stanford Graduate School of Business
| 2 years |
Gary Lauder | M | 61 |
Stanford Graduate School of Business
| 2 years |
Lionel Ivashkiv | M | - |
Harvard Medical School
| 3 years |
Anna Bakst | F | 63 |
Stanford Graduate School of Business
| 2 years |
Sang-Man Han | M | 63 |
Stanford Graduate School of Business
| 2 years |
Kathleen Larrimer Beckmann | F | - |
Stanford Graduate School of Business
| 2 years |
Lishan Aklog | M | 58 |
Harvard Medical School
| 4 years |
Peter Westley | M | 59 |
Stanford Graduate School of Business
| 2 years |
Michael E. Greenberg | M | 69 |
Harvard Medical School
| - |
Paul Gaitan | M | 65 |
Stanford Graduate School of Business
| 2 years |
Matthew le Merle | M | - |
Stanford Graduate School of Business
| 2 years |
Lisa Westley | F | - |
Stanford Graduate School of Business
| 2 years |
Howard Golub | M | 71 |
Harvard Medical School
| 3 years |
Geoff Stein | M | - |
Stanford Graduate School of Business
| 2 years |
Daniel Mintz | M | 61 |
Stanford Graduate School of Business
| 2 years |
Robert Kelly | M | 64 |
Stanford Graduate School of Business
| 2 years |
Marjorie Sennett | F | 63 |
Stanford Graduate School of Business
| 2 years |
Mark Jung | M | 61 |
Stanford Graduate School of Business
| 2 years |
William Ford | M | 61 |
Stanford Graduate School of Business
| 2 years |
Graham K. Crooke | M | 65 |
Stanford Graduate School of Business
| 2 years |
Emily Alejos | F | - |
Stanford Graduate School of Business
| 2 years |
Wendell Wiley Birkhofer | M | - |
Stanford Graduate School of Business
| 2 years |
Peter H. Ziebelman | M | - |
Stanford Graduate School of Business
| 1 years |
Kevin Conn | M | - |
Stanford Graduate School of Business
| 2 years |
Linda Riefler | F | 63 |
Stanford Graduate School of Business
| 2 years |
Srikant T. Madhav Datar | M | 70 |
Stanford Graduate School of Business
| 7 years |
Patricia Nakache | F | 58 |
Stanford Graduate School of Business
| 2 years |
Gregory Shove | M | - |
Stanford Graduate School of Business
| 4 years |
Daniel Swisher | M | 61 |
Stanford Graduate School of Business
| 2 years |
Joseph Abraham | M | - |
Stanford Graduate School of Business
| 2 years |
David Y. Liu | M | 73 |
Harvard Medical School
| 10 years |
Ken B. Sawyer | M | 59 |
Stanford Graduate School of Business
| 2 years |
Daniel Javier Servitje Montull | M | 64 |
Stanford Graduate School of Business
| 2 years |
Carlos Alves de Brito | M | 63 |
Stanford Graduate School of Business
| 2 years |
Stephen Olsen | M | - |
Stanford Graduate School of Business
| 2 years |
Paul Lew Davies | M | - |
Stanford Graduate School of Business
| 2 years |
Bill Joseph Amelio | M | 66 |
Stanford Graduate School of Business
| 1 years |
Sanjay Hiralal Patel | M | 63 |
Stanford Graduate School of Business
| 2 years |
Jeffrey Jordan | M | 65 |
Stanford Graduate School of Business
| 2 years |
Mark Richardson | M | - |
Stanford Graduate School of Business
| 2 years |
Jennifer Fate-Velaise | F | - |
Stanford Graduate School of Business
| 2 years |
Kirk Holmes | M | - |
Stanford Graduate School of Business
| 2 years |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 51 | 51.00% |
Norway | 25 | 25.00% |
Netherlands | 24 | 24.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Jan Hendrik Egberts
- Personal Network